Morgan Stanley Medicenna Therapeutics Corp. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.83 - $1.78 $166,000 - $356,000	-200,000 Reduced 99.11%	1,800 $1,000
Q2 2022 Oct 27, 2022	BUY	$0.79 - $1.32 $156,404 - $261,334	197,981 Added 5184.11%	201,800 $234,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $1.32 $156,404 - $261,334	197,981 Added 5184.11%	201,800 $234,000
Q1 2022 Oct 27, 2022	SELL	$1.26 - $1.92 $249,456 - $380,123	-197,981 Reduced 98.11%	3,819 $5,000
Q1 2022 May 13, 2022	SELL	$1.26 - $1.92 $4,436 - $6,760	-3,521 Reduced 47.97%	3,819 $5,000
Q4 2021 Feb 14, 2022	SELL	$1.53 - $2.85 $47,835 - $89,105	-31,265 Reduced 80.99%	7,340 $12,000
Q3 2021 Nov 15, 2021	BUY	$1.91 - $3.05 $73,735 - $117,745	38,605 New	38,605 $107,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.